Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.54 |
| ▸ | FLT3 | P36888 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 3/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA7 | P43166 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18053822 | 1.00 | KDR (0.67) | KDRKMT2ATRPV1PDGFRBFLT3 | |
| SCHEMBL30481107 | 1.00 | KDR (0.67) | KDRKMT2ATRPV1PDGFRBFLT3 | |
| SCHEMBL20481323 | 0.89 | KDR (0.65) | KDRTRPV1PDGFRBFLT3CA9 | |
| SCHEMBL18053835 | 0.89 | KMT2A (0.63) | KDRKMT2ATRPV1PDGFRBFLT3 | |
| SCHEMBL30481102 | 0.89 | KDR (0.65) | KDRTRPV1PDGFRBFLT3CA9 | |
| SCHEMBL18037989 | 0.85 | KMT2A (0.70) | KDRKMT2ACA9CA1CA2 | |
| SCHEMBL30151307 | 0.85 | KMT2A (0.70) | KDRKMT2ACA9CA1CA2 | |
| SCHEMBL30503358 | 0.85 | KDR (0.65) | KDRKMT2ATRPV1PDGFRBFLT3 | |
| SCHEMBL18038020 | 0.84 | KMT2A (0.62) | KMT2ACA9CA1CA2ALDH1A1 | |
| SCHEMBL23258356 | 0.83 | KDR (0.56) | KDRTRPV1PDGFRBFLT3CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3261631-B1 | INHIBITION OF OLIG2 ACTIVITY | CURTANA PHARMACEUTICALS INC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20230271926-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2023-08-31 | — | — | US | disclosed |
| US-11691951-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691951-B2 | Inhibition of Olig2 activity | GLI2, ING2, GMFG | KDR 1402/4885KMT2A 501/4885TRPV1 4556/4885 |
| US-20230271926-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | KDR 1402/4885KMT2A 501/4885TRPV1 4556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.